Over the last 12 months, Google’s efforts to use artificial intelligence to accelerate drug design have achieved breakthroughs in mimicking human biology and won its top scientists the Nobel Prize in Chemistry. Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor. Isomorphic plans to announce on Monday that it has raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI. GV, Google’s venture capital arm, and Alphabet, Google’s parent company, also invested. The announcement underscores Google’s ambitions for Isomorphic, which was spun out of the company’s DeepMind lab to focus on drugs discovery.

Full report : Isomorphic Labs, a DeepMind spinoff focusing on drug discovery, raised $600M led by Thrive to research treatments, including for cancer and immune disorders.